Treatment of Mycobacterium Xenopi Pulmonary Infection
Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the 6-months sputum conversion rate with a
clarithromycin or moxifloxacin containing regimen in patients with a M. xenopi pulmonary
infection.
Phase:
Phase 3
Details
Lead Sponsor:
Centre Hospitalier Universitaire, Amiens
Treatments:
Clarithromycin Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination